Please assess the completion status of the following clinical trial:

Trial Title: MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria, Common to all MsFLASH Studies:~* Females aged 40-62 years.~* Menopausal, including:~  * Women with a uterus who have skipped 2 or more menstrual cycles with an amenorrhea interval ≥60 days in the past 12 months.~ * Women who have had a bi-lateral oophorectomy (surgical removal of both ovaries).~ * Women without a uterus who still have ovaries, under certain conditions determined during screening.~* Having bothersome hot flashes.~* In general good health as determined by medical history and physical measures.~* Signed informed consent.~Exclusion Criteria, Common to all MsFLASH Studies:~* Use of hormone therapy or hormonal contraceptives during the 2 months before enrollment and for the duration of the study. Certain exceptions apply, determined during screening.~* Use of any other therapy that is taken specifically for hot flashes, including prescription, over-the-counter, or herbal therapies in the past month and duration of the study.~* Any current severe or unstable medical illness.~* Uncontrolled hypertension (\>160/100) or resting heart rate \>110.~* History of endometrial or ovarian cancer; MI, angina, or cerebrovascular events.~* Pregnancy, intending pregnancy, breast feeding.~* Current participation in another drug trial or intervention study.~* Inability or unwillingness to complete the study procedures.~* Certain other conditions, determined during screening.~Exclusion Criteria, Specific to MsFLASH-01:~* Use of selective estrogen receptor modulators (SERMS) or aromatase inhibitors during the two months before enrollment.~* Use of gabapentin, pregabalin, triptans, warfarin (Coumadin®), or St. John's Wort.~* Known hypersensitivity to escitalopram (Lexapro®) or citalopram (Celexa®).~* Use of antidepressants during the past 30 days before starting Study 01, including SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and anxiolytics.~* Not using a medically approved method of birth control, if sexually active and not 12 or more months since last menstrual period.~* History of liver, gall bladder, renal disease, or uncontrolled seizure disorder.~* Certain other conditions, determined during screening.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
- Placebo (Type: PLACEBO_COMPARATOR): Inactive pill

Based on this trial design, predict the completion outcome and termination type (if applicable).